{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:31:17Z","timestamp":1787729477249,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA046910"],"award-info":[{"award-number":["1R01DA046910"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.josat.2023.209214","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:51:49Z","timestamp":1701366709000},"page":"209214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["State guidance and system changes related to COVID-19: Impact on opioid treatment programs"],"prefix":"10.1016","volume":"158","author":[{"given":"Douglas B.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gryczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Halsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon Gwin","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Whitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.josat.2023.209214_bb0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.josat.2023.209214_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108590","article-title":"Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year","volume":"133","author":"Bart","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209214_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2023.209214_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108139","article-title":"Revising our attitudes towards agonist medications and their diversion in a time of pandemic","volume":"119","author":"Del Pozo","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209214_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108246","article-title":"A chance to do it better: Methadone maintenance treatment in the age of COVID-19","volume":"123","author":"Frank","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2023.209214_bb0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment","volume":"41","author":"Green","year":"2020","journal-title":"Substance Abuse"},{"issue":"10","key":"10.1016\/j.josat.2023.209214_bb0040","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.mayocp.2020.08.011","article-title":"Overdue for an overhaul: How opioid treatment programs can learn From COVID-19","volume":"95","author":"Greenblatt","year":"2020","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.josat.2023.209214_bb1025","series-title":"Opioid Treatment Programs Reported Challenges Encountered During the COVID-19 Pandemic and Actions Taken to Address Them","author":"Frontz","year":"2020"},{"key":"10.1016\/j.josat.2023.209214_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108223","article-title":"Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives","volume":"124","author":"Hatch-Maillette","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2023.209214_bb0050","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qualitative Health Research"},{"key":"10.1016\/j.josat.2023.209214_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108163","article-title":"The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19","volume":"120","author":"Hughto","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209214_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108288","article-title":"Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study","volume":"124","author":"Hunter","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2023.209214_bb0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.209214_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108219","article-title":"Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19","volume":"122","author":"Joseph","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.josat.2023.209214_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.209214_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108074","article-title":"Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?","volume":"117","author":"Krawczyk","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2023.209214_bb0085","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/ADM.0000000000000678","article-title":"Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2)","volume":"14","author":"Leppla","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2023.209214_bb0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08897077.2021.1986768","article-title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","volume":"43","author":"Levander","year":"2022","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.209214_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108222","article-title":"Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19","volume":"122","author":"Livingston","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.josat.2023.209214_bb0100","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"8","key":"10.1016\/j.josat.2023.209214_bb0105","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/add.15886","article-title":"State policy uptake does not require formal action: A comment on Nesoff et al","volume":"117","author":"McIlveen","year":"2022","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2023.209214_bb0110","series-title":"Medications for opioid use disorder save lives","year":"2019"},{"key":"10.1016\/j.josat.2023.209214_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108196","article-title":"Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?","volume":"122","author":"Nunes","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.josat.2023.209214_bb0120","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/add.15143","article-title":"Time to revisit uneven policy in the United States for medication for opioid use disorder during COVID-19","volume":"115","author":"Pena","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.josat.2023.209214_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ADM.0000000000000841","article-title":"Permanent methadone treatment reform needed to combat the opioid crisis and structural racism","volume":"16","author":"Peterkin","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.209214_bb0130","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.josat.2023.209214_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108263","article-title":"Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder","volume":"123","author":"Stringer","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209214_bb0140","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.josat.2023.209214_bb0145","series-title":"Medications for opioid use disorder: Treatment Improvement Protocol (TIP) Series 63","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2021"},{"key":"10.1016\/j.josat.2023.209214_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108394","article-title":"The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?","volume":"131","author":"Tracy","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209214_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms","volume":"132","author":"Treitler","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"22","key":"10.1016\/j.josat.2023.209214_bb0160","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"The New England Journal of Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:11:36Z","timestamp":1778937096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923002655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"alternative-id":["S2949875923002655"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209214","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State guidance and system changes related to COVID-19: Impact on opioid treatment programs","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209214"}}